BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21740381)

  • 1. RNA interference and amyotrophic lateral sclerosis.
    Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
    Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference protects against ALS in mouse model.
    Burton A
    Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
    [No Abstract]   [Full Text] [Related]  

  • 5. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.
    Kaur SJ; McKeown SR; Rashid S
    Gene; 2016 Feb; 577(2):109-18. PubMed ID: 26657039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyotrophic lateral sclerosis: pathogenesis.
    Brown RH; Robberecht W
    Semin Neurol; 2001 Jun; 21(2):131-9. PubMed ID: 11442322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

  • 10. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS.
    Hayashi Y; Homma K; Ichijo H
    Adv Biol Regul; 2016 Jan; 60():95-104. PubMed ID: 26563614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells.
    Oh YK; Shin KS; Yuan J; Kang SJ
    J Neurochem; 2008 Feb; 104(4):993-1005. PubMed ID: 18233996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
    Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutations: neuronal Lewy body-like hyaline inclusions and astrocytic hyaline inclusions.
    Kato S; Saito M; Hirano A; Ohama E
    Histol Histopathol; 1999 Jul; 14(3):973-89. PubMed ID: 10425565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
    Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
    Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
    Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyotrophic lateral sclerosis-related mutant superoxide dismutase 1 aggregates inhibit 14-3-3-mediated cell survival by sequestration into the JUNQ compartment.
    Park JH; Jang HR; Lee IY; Oh HK; Choi EJ; Rhim H; Kang S
    Hum Mol Genet; 2017 Sep; 26(18):3615-3629. PubMed ID: 28666328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of amyotrophic lateral sclerosis.
    Robberecht W
    J Neurol; 2000 Dec; 247 Suppl 6():VI/2-6. PubMed ID: 19714405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.